Next Article in Journal
Fluoropolymer-Containing Opals and Inverse Opals by Melt-Shear Organization
Previous Article in Journal
Novel Cucurbitane Triterpenes from the Tubers of Hemsleya amabilis with Their Cytotoxic Acitivity
Previous Article in Special Issue
Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights
Article Menu
Issue 2 (January-2) cover image

Export Article

Open AccessArticle
Molecules 2019, 24(2), 332; https://doi.org/10.3390/molecules24020332

Large Pore Mesoporous Silica and Organosilica Nanoparticles for Pepstatin A Delivery in Breast Cancer Cells

1
Institut Charles Gerhardt Montpellier, UMR-5253 Univ Montpellier, CNRS, ENSCM, cc 1701, Place Eugène Bataillon, CEDEX 5, 34095 Montpellier, France
2
Institut des Biomolécules Max Mousseron, UMR 5247 CNRS, UM-Faculté de Pharmacie, 15 Avenue Charles Flahault, CEDEX 5, 34093 Montpellier, France
3
NanoMedSyn, Faculté de Pharmacie, 15 Avenue Charles Flahault, CEDEX 5, 34093, Montpellier, France
4
Centre de Recherche en Biologie cellulaire de Montpellier (CRBM), UMR 5237 CNRS, Université Montpellier, 1919 Route de Mende, CEDEX 5, 34293 Montpellier, France
*
Authors to whom correspondence should be addressed.
Received: 11 December 2018 / Revised: 9 January 2019 / Accepted: 11 January 2019 / Published: 17 January 2019
(This article belongs to the Special Issue Mesoporous Silica in Biomedical Applications)
Full-Text   |   PDF [2606 KB, uploaded 22 January 2019]   |  

Abstract

(1) Background: Nanomedicine has recently emerged as a new area of research, particularly to fight cancer. In this field, we were interested in the vectorization of pepstatin A, a peptide which does not cross cell membranes, but which is a potent inhibitor of cathepsin D, an aspartic protease particularly overexpressed in breast cancer. (2) Methods: We studied two kinds of nanoparticles. For pepstatin A delivery, mesoporous silica nanoparticles with large pores (LPMSNs) and hollow organosilica nanoparticles (HOSNPs) obtained through the sol–gel procedure were used. The nanoparticles were loaded with pepstatin A, and then the nanoparticles were incubated with cancer cells. (3) Results: LPMSNs were monodisperse with 100 nm diameter. HOSNPs were more polydisperse with diameters below 100 nm. Good loading capacities were obtained for both types of nanoparticles. The nanoparticles were endocytosed in cancer cells, and HOSNPs led to the best results for cancer cell killing. (4) Conclusions: Mesoporous silica-based nanoparticles with large pores or cavities are promising for nanomedicine applications with peptides. View Full-Text
Keywords: pepstatin A; mesoporous silica nanoparticles; mesoporous organosilica nanoparticles; cancer pepstatin A; mesoporous silica nanoparticles; mesoporous organosilica nanoparticles; cancer
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Rahmani, S.; Budimir, J.; Sejalon, M.; Daurat, M.; Aggad, D.; Vives, E.; Raehm, L.; Garcia, M.; Lichon, L.; Gary-Bobo, M.; Durand, J.-O.; Charnay, C. Large Pore Mesoporous Silica and Organosilica Nanoparticles for Pepstatin A Delivery in Breast Cancer Cells. Molecules 2019, 24, 332.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top